European Pharmaceutical Review

JULY 4, 2024

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 13 Currently, over 350 herbal remedies have been granted a THR licence. 2012/1916).

Drug Development 103

Drug Development Biosimilars Documentation Labelling 103

pharmaphorum

FEBRUARY 18, 2021

Eli Lilly’s Humalog compound and formulation patents expired in 2013 and 2014, respectively. In late 2017, the FDA approved Admelog, Sanofi’s biosimilar of Humalog. AstraZeneca’s patent for its top-selling gastroesophageal reflux disease drug was due to expire in 2001. Prilosec – Benchmark for franchise management.

Prescription Filling 52

Prescription Filling Drug Pricing Biosimilars Compounding 52

FDA Law Blog: Biosimilars

FEBRUARY 11, 2024

Not surprisingly, then-presidential candidate Asa Hutchinson, DEA Administrator from 2001 to 2003, did not sign the letter. The letter is signed by six former DEA administrators and five former Directors of National Drug Policy. The earliest tenured is John Bartels, who served as Administrator from 1973 to 1975.

Controlled Substances 59

Controlled Substances Chemotherapy Compounding 59